Список литературы

2687-0940

Актуальные проблемы медицины

2687-0940

10.52575/2687-0940-2024-47-2-158-170

191

ВНУТРЕННИЕ БОЛЕЗНИ

<strong>Современные терапевтические подходы к лечению алкогольного гепатита</strong>

<strong>Modern Therapeutic Approaches to the Treatment of Alcoholic Hepatitis</strong>

Усанова

Анна Александровна

Usanova

Anna A.

Кузма

Фади

Kuzma

Fadi

fadykuzma@mail.ru

Новикова

Эльвира Камилевна

Novikova

Elvira K.

Сергутова

Наталья Петровна

Sergutova

Natalya P.

2024

47200

Лечение алкогольного гепатита имеет решающее значение для улучшения выживаемости и предотвращения прогрессирования заболевания до цирроза и печеночной недостаточности. Традиционные методы лечения, такие как воздержание от алкоголя и симптоматическая медикаментозная терапия, остаются краеугольными камнями лечения. Однако в последние годы появились новые препараты, которые показали многообещающие результаты в улучшении исходов у пациентов с алкогольным гепатитом. Целью данного обзора является представление наиболее актуальных немедикаментозных, медикаментозных подходов в лечении данной группы пациентов, а также решение вопроса о необходимости ранней трансплантации печени.  В задачи работы входили сбор современных научных данных; обсуждение специфики каждого метода лечения, возможные ограничения в контексте применения у данной группы пациентов, основные преимущества для больных с алкогольным гепатитом; анализ результатов исследований, которые подчеркивают значимость используемых лекарственных препаратов в рутинной практике в зависимости от степени тяжести заболевания. Результаты работы подчеркивают сохранение необходимости использования немедикаментозных методов и по результатам применения валидированных шкал назначение индивидуальной медикаментозной терапии, а также необходимость дальнейших исследований для оптимизации результатов у данной группы пациентов.

Treatment of alcoholic hepatitis is critical to improve survival and prevent progression to cirrhosis and liver failure. Traditional treatments, such as alcohol abstinence and symptomatic drug therapy, remain the cornerstones of treatment. However, in recent years, new drugs have emerged that have shown promise in improving outcomes in patients with alcoholic hepatitis. The purpose of this review is to present the most relevant non-drug, drug-based approaches in the treatment of this group of patients, as well as address the issue of the need for early liver transplantation. The objectives of the work included collecting modern scientific data; discussion of the specifics of each treatment method, possible limitations in the context of use in this group of patients, main advantages for patients with alcoholic hepatitis; analysis of research results that highlight the importance of the drugs used in routine practice depending on the severity of the disease. The results of the work emphasize the continued need to use non-drug methods and, based on the results of using validated scales, prescribe individual drug therapy, as well as the need for further research to optimize results in this group of patients.

алкогольная болезнь печениалкогольный гепатитциррозпеченочная недостаточностьпентоксифиллинларсукостерол

alcoholic liver diseasealcoholic hepatitiscirrhosisliver failurepentoxifyllinelarsucosterol

Работа выполнена без внешних источников финансирования.

Список литературы

Allen S.L., Quinlan J.I., Dhaliwal A., Armstrong M.J., Elsharkawy A.M., Greig C.A., Lord J.M., Lavery G.G., Breen L. 2020. Sarcopenia in Chronic Liver Disease: Mechanisms and Countermeasures. American Journal of Physiology. Gastrointestinal and Liver Physiology. 320(3): 241–257. https://doi.org/10.1152/ajpgi.00373.2020

Arab J.P., Roblero J.P., Altamirano J., Bessone F., Chaves Araujo R., Higuera-De la Tijera F., Restrepo J.C., Torre A., Urzua A., Simonetto D.A., Abraldes J.G., Méndez-Sánchez N., Contreras F., Lucey M.R., Shah V.H., Cortez-Pinto H., Bataller R. 2019. Alcohol-Related Liver Disease: Clinical Practice Guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of Hepatology. 18(3): 518–535. https://doi.org/10.1016/j.aohep.2019.04.005

Arab J.P., Díaz L.A., Baeza N., Idalsoaga F., Fuentes-López E., Arnold J., Ramírez C.A., Morales-Arraez D., Ventura-Cots M., Alvarado-Tapias E., Zhang W., Clark V., Simonetto D., Ahn J.C., Buryska S., Mehta T.I., Stefanescu H., Horhat A., Bumbu A., Dunn W., Bataller R. 2021. Identification of Optimal Therapeutic Window for Steroid Use in Severe Alcohol-Associated Hepatitis: A Worldwide Study. Journal of Hepatology. 75(5): 1026–1033. https://doi.org/10.1016/j.jhep.2021.06.019

Baig M., Walayat S., Dhillon S., Puli S. 2020. Efficacy of Granulocyte Colony Stimulating Factor in Severe Alcoholic Hepatitis: A Systematic Review and Meta-Analysis. Cureus. 12(9): 10474. https://doi.org/10.7759/cureus.10474

Bischoff S.C., Bernal W., Dasarathy S., Merli M., Plank L.D., Schütz T., Plauth M. 2020. ESPEN Practical Guideline: Clinical Nutrition in Liver Disease. Clinical Nutrition (Edinburgh, Scotland). 39(12): 3533–3562. https://doi.org/10.1016/j.clnu.2020.09.001

Clemente-Sánchez A., Oliveira-Mello A., Bataller R. 2021. Moderate Alcoholic Hepatitis. Clinics in Liver Disease. 25(3): 537–555. https://doi.org/10.1016/j.cld.2021.03.001

Dingwall K.M., Delima J.F., Binks P., Batey R., Bowden S.C. 2022. What is the Optimum Thiamine Dose to Treat or Prevent Wernicke's Encephalopathy or Wernicke-Korsakoff Syndrome? Results of a Randomized Controlled Trial. Alcoholism, Clinical and Experimental Research. 46(6): 1133–1147. https://doi.org/10.1111/acer.14843

Dominguez M., Rincón D., Abraldes J.G., Miquel R., Colmenero J., Bellot P., García-Pagán J.C., Fernández R., Moreno M., Bañares R., Arroyo V., Caballería J., Ginès P., Bataller R. 2008. A New Scoring System for Prognostic Stratification of Patients with Alcoholic Hepatitis. The American Journal of Gastroenterology. 103(11): 2747–2756. https://doi.org/10.1111/j.1572-0241.2008.02104.x

Eslamian G., Ardehali S.H., Baghestani A.R., Vahdat Shariatpanahi Z. 2019. Effects of Early Enteral Bovine Colostrum Supplementation on Intestinal Permeability in Critically Ill Patients: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrition (Burbank, Los Angeles County, Calif.). 60: 106–111. https://doi.org/10.1016/j.nut.2018.10.013

Frenette C.T., Morelli G., Shiffman M.L., Frederick R.T., Rubin R.A., Fallon M.B., Cheng J.T., Cave M., Khaderi S.A., Massoud O., Pyrsopoulos N., Park J.S., Robinson J.M., Yamashita M., Spada A.P., Chan J.L., Hagerty D.T. 2019. Emricasan Improves Liver Function in Patients with Cirrhosis and High Model for End-Stage Liver Disease Scores Compared with Placebo. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association. 17(4): 774–783. https://doi.org/10.1016/j.cgh.2018.06.012

Galvin R., Bråthen G., Ivashynka A., Hillbom M., Tanasescu R., Leone M.A., 2010. EFNS Guidelines for Diagnosis, Therapy and Prevention of Wernicke Encephalopathy. European Journal of Neurology. 17(12): 1408–1418. https://doi.org/10.1111/j.1468-1331.2010.03153.x

Gao B. 2015. Interplay of Interleukin-22 and its Binding Protein in Controlling Liver Scarring. Hepatology (Baltimore, Md.). 61(4): 1121–1123. https://doi.org/10.1002/hep.27688

Gao B. Bataller R. 2011. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterology. 141(5): 1572–1585. https://doi.org/10.1053/j.gastro.2011.09.002

Hammad A., Kaido T., Aliyev V., Mandato C., Uemoto S. 2017. Nutritional Therapy in Liver Transplantation. Nutrients. 9(10): 1126. https://doi.org/10.3390/nu9101126

Hartmann P., Hochrath K., Horvath A., Chen P., Seebauer C.T., Llorente C., Wang L., Alnouti Y., Fouts D.E., Stärkel P., Loomba R., Coulter S., Liddle C., Yu R.T., Ling L., Rossi S.J., DePaoli A.M., Downes M., Evans R.M., Brenner D.A., Schnabl B. 2018. Modulation of the Intestinal Bile Acid/Farnesoid X Receptor/Fibroblast Growth Factor 15 Axis Improves Alcoholic Liver Disease in Mice. Hepatology (Baltimore, Md.). 67(6): 2150–2166. https://doi.org/10.1002/hep.29676

Hassanein T., McClain C.J., Vatsalya V., Stein L.L., Flamm S.L., Martin P., Cave M.C., Mitchell M. Jr., Barton B., Nagy L., Szabo G., McCullough A., Dasarathy S., Shah J., Blevins C., Scott D., Krebs W., Brown J.E., Lin W. 2024. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. The American Journal of Gastroenterology. 119(1): 107–115. https://doi.org/10.14309/ajg.0000000000002275

Hassanein T., Stein L.L., Flamm S.L., Martin P., Cave M.C., Blevins C., Scott D., Krebs W., Lin W. 2019. Safety and Efficacy of DUR-928: a Potential New Therapy for Acute Alcoholic Hepatitis. Hepatology. 70: 1483A-1484A.

Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. 2018. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology (Baltimore, Md.). 67(1): 358–380. https://doi.org/10.1002/hep.29086.

Hendrikx T., Duan Y., Wang Y., Oh J.H., Alexander L.M., Huang W., Stärkel P., Ho S.B., Gao B., Fiehn O., Emond P., Sokol H., van Pijkeren J.P., Schnabl B. 2019. Bacteria Engineered to Produce IL-22 in Intestine Induce Expression of REG3G to Reduce Ethanol-Induced Liver Disease in Mice. Gut. 68(8): 1504–1515. https://doi.org/10.1136/gutjnl-2018-317232

Jepsen P., Younossi Z.M. 2021. The Global Burden of Cirrhosis: A Review of Disability-Adjusted Life-Years Lost and Unmet Needs. Journal of Hepatology. 75(1): 3–13. https://doi.org/10.1016/j.jhep.2020.11.042

Louvet A., Trabut J.B., Moreno C., Moirand R., Aubin H.J., Ntandja Wandji L.C., Nourredine M., Ningarhari M., Ganne-Carrié N., Pageaux G.P., Bailly F., Boursier J., Daeppen J.B., Luquiens A., Nguyen-Khac E., Anty R., Orban T., Donnadieu-Rigole H., Mallat, A., Bureau C., for the Groupe Collaboratif AFEF-SFA Maladie du foie liée à l'alcool 2022. Management of Alcohol-Related Liver Disease: the French Association for the Study of the Liver and the French Alcohol Society Clinical Guidelines. Liver International : Official Journal of the International Association for the Study of the Liver. 42(6): 1330–1343. https://doi.org/10.1111/liv.15221

Mathurin P., Deng Q.G., Keshavarzian A., Choudhary S., Holmes E.W., Tsukamoto H. 2000. Exacerbation of Alcoholic Liver Injury by Enteral Endotoxin in Rats. Hepatology (Baltimore, Md.). 32(5): 1008–1017. https://doi.org/10.1053/jhep.2000.19621

Mayr U., Pfau J., Lukas M., Bauer U., Herner A., Rasch, S., Schmid, R.M., Huber W., Lahmer T.,

Batres-Baires G. 2020. NUTRIC and Modified NUTRIC are Accurate Predictors of Outcome in End-Stage Liver Disease: A Validation in Critically ill Patients with Liver Cirrhosis. Nutrients. 12(7): 2134. https://doi.org/10.3390/nu12072134

McClain C.J., Rios C.D., Condon S., Marsano L.S. 2021. Malnutrition and Alcohol-Associated Hepatitis. Clinics in Liver Disease. 25(3): 557–570. https://doi.org/10.1016/j.cld.2021.03.002

Mendenhall C., Roselle G.A., Gartside P., Moritz T. 1995. Relationship of Protein Calorie Malnutrition to Alcoholic Liver Disease: a Reexamination of Data from Two Veterans Administration Cooperative Studies. Alcoholism, Clinical and Experimental Research. 19(3): 635–641. https://doi.org/10.1111/j.1530-0277.1995.tb01560.x

Meza V., Arnold J., Díaz L.A., Ayala Valverde M., Idalsoaga F., Ayares G., Devuni D., Arab J.P. 2022. Alcohol Consumption: Medical Implications, the Liver and Beyond. Alcohol and Alcoholism (Oxford, Oxfordshire). 57(3): 283–291. https://doi.org/10.1093/alcalc/agac013

Mishra A.K., Shasthry S.M., Vashishtha C. 2022. GCSF Increases the Steroid Responsiveness and 90 Day Survival in Severe Alcoholic Hepatitis Patients: A Randomised Control Trial. Hepatology. 76: 150.

Morales-Arráez D., Ventura-Cots M., Altamirano J., Abraldes J.G., Cruz-Lemini M., Thursz M.R., Atkinson S.R., Sarin S.K., Kim W., Chavez-Araujo R., Higuera-de la Tijera M.F., Singal A.K., Shah V.H., Kamath P.S., Duarte-Rojo A., Charles E.A., Vargas V., Jager M., Rautou P.E., Rincon D., Bataller R. 2022. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. The American journal of gastroenterology. 117(2): 301–310. https://doi.org/10.14309/ajg.0000000000001596

Nevens F., Andreone P., Mazzella G., Strasser S.I., Bowlus C., Invernizzi P., Drenth J.P., Pockros P.J., Regula J., Beuers U., Trauner M., Jones D.E., Floreani A., Hohenester S., Luketic V., Shiffman M., van Erpecum K.J., Vargas V., Vincent C., Hirschfield G.M., POISE Study Group. 2016. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England Journal of Medicine. 375(7), 631–643. https://doi.org/10.1056/nejmoa1509840

Periyalwar P., Dasarathy S. 2012. Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical Responses. Clinics in Liver Disease. 16(1): 95–131. https://doi.org/10.1016/j.cld.2011.12.009

Seitz H.K., Bataller R., Cortez-Pinto H., Gao B., Gual A., Lackner C., Mathurin P., Muelle, S., Szabo G., Tsukamoto H. 2018. Alcoholic Liver Disease. Nature Reviews. Disease Primers. 4(1): 16. https://doi.org/10.1038/s41572-018-0014-7

Singal A.K., Shah V.H. 2016. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis. Seminars in Liver Disease. 36(1): 56–68. https://doi.org/10.1055/s-0036-1571297

Singal A.K., Mathurin P. 2021. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review. JAMA. 326(2), 165–176. https://doi.org/10.1001/jama.2021.7683

Subramaniyan V., Chakravarthi S., Jegasothy R., Seng W.Y., Fuloria N. K., Fuloria S., Hazarika I., Das A. 2021. Alcohol-Associated Liver Disease: A Review on its Pathophysiology, Diagnosis and Drug Therapy. Toxicology Reports. 8: 376–385. https://doi.org/10.1016/j.toxrep.2021.02.010

Swart G.R., Zillikens M.C., van Vuure J.K., van den Berg J.W. 1989. Effect of a Late Evening Meal on Nitrogen Balance in Patients with Cirrhosis of the Liver. BMJ (Clinical Research Ed.). 299(6709): 1202–1203. https://doi.org/10.1136/bmj.299.6709.1202

Tayek J.A., Stolz A.A., Nguyen D.V., Fleischman M.W., Donovan J.A., Alcorn J.M., Chao D.C., Asghar A., Morgan T.R. Southern California Alcoholic Hepatitis (SCAH) Consortium 2022. A Phase II, Multicenter, Open-Label, Randomized Trial of Pegfilgrastim for Patients with Alcohol-Associated Hepatitis. E. Clinical Medicine, 54: 101689. https://doi.org/10.1016/j.eclinm.2022.101689

Xiang X., Hwang S., Feng D., Shah V.H., Gao B. 2020. Interleukin-22 in Alcoholic Hepatitis and Beyond. Hepatology International. 14(5): 667–676. https://doi.org/10.1007/s12072-020-10082-6

Zhang Y., Ma J., Jing N., Zhang H., Xie Y., Liu H., Shan X., Ren J., Jin J. 2023. Bifidobacterium animalis A12 and Lactobacillus salivarius M18-6 Alleviate Alcohol Injury by keap1-Nrf2 Pathway and Thioredoxin System. Foods (Basel, Switzerland). 12(3): 439. https://doi.org/10.3390/foods12030439